Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States.
Saved in:
| Title: | Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States. |
|---|---|
| Authors: | Daniel SR; Evidence Generation, Labcorp Drug Development, Gaithersburg, MD, USA., Gandhi K; Patient & Health Impact, Pfizer, Collegeville, PA, USA., Anastassopoulos KP; Evidence Generation, Labcorp Drug Development, Gaithersburg, MD, USA., Pandya AG; Department of Dermatology, Palo Alto Foundation Medical Group, Sunnyvale, CA, USA.; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Sikirica V; Patient & Health Impact, Pfizer, Collegeville, PA, USA., Patel R; Evidence Generation, Labcorp Drug Development, Gaithersburg, MD, USA., Napatalung L; Medical Affairs, Pfizer, New York, NY, USA.; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Yamaguchi Y; Inflammation & Immunology Research Unit, Pfizer, Collegeville, PA, USA., Baik R; Evidence Generation, Labcorp Drug Development, Gaithersburg, MD, USA., Ezzedine K; Department of Dermatology, Hôpital Henri Mondor, Créteil, France. |
| Source: | The British journal of dermatology [Br J Dermatol] 2022 Oct; Vol. 187 (4), pp. 603-606. Date of Electronic Publication: 2022 Jun 29. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
